Department of Emergency Medicine in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Department of Urgent Care in Linköping, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Ups J Med Sci. 2023 May 3;128. doi: 10.48101/ujms.v128.9300. eCollection 2023.
Predicting the risk of readmission or death in patients at the emergency department (ED) is essential in identifying patients who would benefit the most from interventions. We aimed to explore the prognostic value of mid-regional proadrenomedullin (MR-proADM), mid-regional pro-atrial natriuretic peptide (MR-proANP), copeptin, and high-sensitivity troponin T (hs-TnT) to identify patients with a higher risk of readmission and death among patients presenting with chest pain (CP) and/or shortness of breath (SOB) in the ED.
This single-center prospective observational study included non-critically ill adult patients with a chief complaint of CP and/or SOB who visited the ED at Linköping University Hospital. Baseline data and blood samples were collected, and patients were followed up for 90 days after inclusion. The primary outcome was a composite of readmission and/or death from non-traumatic causes within 90 days of inclusion. Binary logistic regression was used and receiver operating characteristics (ROC) curves were constructed to determine the prognostic performance for predicting readmission and/or death within 90 days.
A total of 313 patients were included and 64 (20.4%) met the primary endpoint. MR-proADM > 0.75 pmol/L (odds ratio [OR]: 2.361 [95% confidence interval [CI]: 1.031 - 5.407], = 0.042) and multimorbidity (OR: 2.647 [95% CI: 1.282 - 5.469], = 0.009) were significantly associated with readmission and/or death within 90 days. MR-proADM increased predictive value in the ROC analysis to age, sex, and multimorbidity ( = 0.006).
In non-critically ill patients with CP and/or SOB in the ED, MR-proADM and multimorbidity may be helpful for the prediction of the risk of readmission and/or death within 90 days.
在急诊科(ED)预测再入院或死亡的风险对于确定最需要干预的患者至关重要。我们旨在探讨中区域原肾上腺素(MR-proADM)、中区域原心钠肽(MR-proANP)、 copeptin 和高敏肌钙蛋白 T(hs-TnT)的预后价值,以识别因胸痛(CP)和/或呼吸急促(SOB)就诊于 ED 的患者中再入院和死亡风险较高的患者。
这项单中心前瞻性观察性研究纳入了因 CP 和/或 SOB 主诉就诊于林雪平大学医院 ED 的非危重症成年患者。收集基线数据和血液样本,并在纳入后随访 90 天。主要结局是纳入后 90 天内非创伤性原因再入院和/或死亡的复合终点。采用二元逻辑回归和受试者工作特征(ROC)曲线来确定预测 90 天内再入院和/或死亡的预后性能。
共纳入 313 例患者,64 例(20.4%)达到主要终点。MR-proADM > 0.75 pmol/L(比值比 [OR]:2.361 [95%置信区间 [CI]:1.031 - 5.407], = 0.042)和合并症(OR:2.647 [95% CI:1.282 - 5.469], = 0.009)与 90 天内再入院和/或死亡显著相关。在 ROC 分析中,MR-proADM 增加了对年龄、性别和合并症的预测价值( = 0.006)。
在 ED 因 CP 和/或 SOB 就诊的非危重症患者中,MR-proADM 和合并症可能有助于预测 90 天内再入院和/或死亡的风险。